Delta Variant Spike RBD SARS-CoV-2

<strong>Delta Variant Spike RBD SARS-CoV-2</strong>_x000D_ <strong>Catalog number:</strong> B2010480_x000D_ <strong>Lot number:</strong> Batch Dependent_x000D_ <strong>Expiration Date:</strong> Batch dependent_x000D_ <strong>Amount:</strong> 100 ug_x000D_ <strong>Molecular Weight or Concentration:</strong> 27 kDa_x000D_ <strong>Supplied as:</strong> Lyophilized powder_x000D_ <strong>Appearance:</strong> Powder_x000D_ <strong>Applications:</strong> highly pure (&gt; 95%) SARS-CoV-2 RBD of the Delta Variant. This protein was expressed in HEK293 and has been tested for its ability to bind the human cellular receptor ACE2._x000D_ <strong>Storage:</strong> -20C_x000D_ <strong>Keywords:</strong> Delta RBD, Delta Spike_x000D_ <strong>Grade:</strong> Biotechnology grade. All solid components are highly pure (minimum 95%). All solutions are made with Type I ultrapure water (resistivity &gt;18 MΩ-cm) and are filtered through 0.22 um._x000D_ _x000D_ <a href="https://moleculardepot.com/wp-content/uploads/2022/03/MKT-010-SARS-CoV-2-Brochure-Rev-A.pdf"><strong>Download SARS-CoV-2 Brochure</strong></a>_x000D_ _x000D_ <strong>References:</strong>_x000D_ 1: Weisblum Y, Schmidt F, Zhang F, DaSilva J, Poston D, Lorenzi JC, Muecksch F,_x000D_ Rutkowska M, Hoffmann HH, Michailidis E, Gaebler C, Agudelo M, Cho A, Wang Z,_x000D_ Gazumyan A, Cipolla M, Luchsinger L, Hillyer CD, Caskey M, Robbiani DF, Rice CM,_x000D_ Nussenzweig MC, Hatziioannou T, Bieniasz PD. Escape from neutralizing antibodies_x000D_ by SARS-CoV-2 spike protein variants. Elife. 2020 Oct 28;9:e61312._x000D_ _x000D_ 2: Weisblum Y, Schmidt F, Zhang F, DaSilva J, Poston D, Lorenzi JCC, Muecksch F,_x000D_ Rutkowska M, Hoffmann HH, Michailidis E, Gaebler C, Agudelo M, Cho A, Wang Z,_x000D_ Gazumyan A, Cipolla M, Luchsinger L, Hillyer CD, Caskey M, Robbiani DF, Rice CM,_x000D_ Nussenzweig MC, Hatziioannou T, Bieniasz PD. Escape from neutralizing antibodies_x000D_ by SARS-CoV-2 spike protein variants. bioRxiv [Preprint]. 2020 Jul_x000D_ 22:2020.07.21.214759._x000D_ _x000D_ 3: Zhou Y, Liu Z, Li S, Xu W, Zhang Q, Silva IT, Li C, Wu Y, Jiang Q, Liu Z,_x000D_ Wang Q, Guo Y, Wu J, Gu C, Cai X, Qu D, Mayer CT, Wang X, Jiang S, Ying T, Yuan_x000D_ Z, Xie Y, Wen Y, Lu L, Wang Q. Enhancement versus neutralization by SARS-CoV-2_x000D_ antibodies from a convalescent donor associates with distinct epitopes on the_x000D_ RBD. Cell Rep. 2021 Feb 2;34(5):108699._x000D_ _x000D_ 4: McCallum M, Marco A, Lempp F, Tortorici MA, Pinto D, Walls AC, Beltramello M,_x000D_ Chen A, Liu Z, Zatta F, Zepeda S, di Iulio J, Bowen JE, Montiel-Ruiz M, Zhou J,_x000D_ Rosen LE, Bianchi S, Guarino B, Fregni CS, Abdelnabi R, Caroline Foo SY,_x000D_ Rothlauf PW, Bloyet LM, Benigni F, Cameroni E, Neyts J, Riva A, Snell G, Telenti_x000D_ A, Whelan SPJ, Virgin HW, Corti D, Pizzuto MS, Veesler D. N-terminal domain_x000D_ antigenic mapping reveals a site of vulnerability for SARS-CoV-2. bioRxiv_x000D_ [Preprint]. 2021 Jan 14:2021.01.14.426475._x000D_ _x000D_ 5: Chakraborty S. Evolutionary and structural analysis elucidates mutations on_x000D_ SARS-CoV2 spike protein with altered human ACE2 binding affinity. Biochem_x000D_ Biophys Res Commun. 2021 Jan 1;534:374-380._x000D_ _x000D_ 6: Zahradník J, Marciano S, Shemesh M, Zoler E, Harari D, Chiaravalli J, Meyer_x000D_ B, Rudich Y, Li C, Marton I, Dym O, Elad N, Lewis MG, Andersen H, Gagne M, Seder_x000D_ RA, Douek DC, Schreiber G. SARS-CoV-2 variant prediction and antiviral drug_x000D_ design are enabled by RBD in vitro evolution. Nat Microbiol. 2021 Aug 16._x000D_ _x000D_ 7: Kim S, Liu Y, Lei Z, Dicker J, Cao Y, Zhang XF, Im W. Differential_x000D_ Interactions Between Human ACE2 and Spike RBD of SARS-CoV-2 Variants of Concern._x000D_ bioRxiv [Preprint]. 2021 Jul 26:2021.07.23.453598._x000D_ _x000D_ 8: Carnell GW, Ciazynska KA, Wells DA, Xiong X, Aguinam ET, McLaughlin SH,_x000D_ Mallery D, Ebrahimi S, Ceron-Gutierrez L, Asbach B, Einhauser S, Wagner R, James_x000D_ LC, Doffinger R, Heeney JL, Briggs JAG. SARS-CoV-2 Spike Protein Stabilized in_x000D_ the Closed State Induces Potent Neutralizing Responses. J Virol. 2021 Jul_x000D_ 12;95(15):e0020321._x000D_ _x000D_ 9: Shen X, Tang H, McDanal C, Wagh K, Fischer W, Theiler J, Yoon H, Li D, Haynes_x000D_ BF, Sanders KO, Gnanakaran S, Hengartner N, Pajon R, Smith G, Dubovsky F, Glenn_x000D_ GM, Korber B, Montefiori DC. SARS-CoV-2 variant B.1.1.7 is susceptible to_x000D_ neutralizing antibodies elicited by ancestral Spike vaccines. bioRxiv_x000D_ [Preprint]. 2021 Jan 29:2021.01.27.428516._x000D_ <a href="https://pubmed.ncbi.nlm.nih.gov/34322129/">10: Martínez-Flores D, Zepeda-Cervantes J, Cruz-Reséndiz A, Aguirre-Sampieri S,_x000D_ Sampieri A, Vaca L. SARS-CoV-2 Vaccines Based on the Spike Glycoprotein and_x000D_ Implications of New Viral Variants. Front Immunol. 2021 Jul 12;12:701501. </a>_x000D_ _x000D_ <strong>Products Related to Delta Variant SARS-CoV-2 Spike RBD </strong> <a href="https://moleculardepot.com/product-category/SARS-CoV-2/">: SARS-CoV-2</a>